Skip to Content


Clinical Investigator Training Course

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA), Office of Critical Path Programs and the Clinical Trials Transformation Initiative (CTTI) are cosponsoring a 3-day training course for clinical investigators on scientific, ethical, and regulatory aspects of clinical trials. This training course is intended to provide investigators with expertise in the design, conduct, and analysis of clinical trials; improve the Start Printed Page 45578quality of clinical trials; and enhance the safety of trial participants. Senior FDA staff will communicate directly with clinical investigators on issues of greatest importance for successful clinical research.

Date and Time: The training course will be held on November 7 and 8, 2011, from 8 a.m. to 5 p.m., and on November 9, 2011, from 8 a.m. to 3:30 p.m.

Location: The course will be held at the National Labor College, 10000 New Hampshire Ave., Silver Spring, MD 20903-0002.

Contact Person: Leonard Sacks, Office of Critical Path Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 4174, Silver Spring, MD 20993, 301-796-8502.

Registration: Register by October 21, 2011. The registration fee is $400 per person. The fee includes course materials and onsite lunch. Early registration is recommended because seating is limited. There will be no onsite registration.

Register online for the training course at the registration/information Web site at​fda-clinical-investigator-training-course or by FAX to 919-660-1769. An e-mail will be sent confirming your registration.

Attendees are responsible for their own accommodations. A block of rooms has been reserved under “FDA Clinical Investigator Course” at the National Labor College at a reduced conference rate. Reservations can be made at​Room_​Reservations.html or by calling 301-431-6400. FDA has verified the Web site address, but is not responsible for subsequent changes to the Web site after this document publishes in the Federal Register.

Registration materials, payment procedures, accommodation information, and a detailed description of the course can be found at​fda-clinical-investigator-training-course.

If you need special accommodations due to a disability, please contact Leonard Sacks at least 7 days in advance. Persons attending the course are advised that FDA is not responsible for providing access to electrical outlets.

End Preamble Start Supplemental Information


I. Background

Clinical trial investigators play a critical role in the development of medical products. They bear the responsibility for ensuring the safe and ethical treatment of study subjects and for acquiring adequate and reliable data to support regulatory decisions. This course is intended to assist clinical investigators in understanding what preclinical and clinical information is needed to support the investigational use of medical products, as well as the scientific, regulatory, and ethical considerations involved in the conduct of clinical trials. The course will cover a wide variety of key topics, including material on novel safety concerns, adverse event monitoring, compliance with the legal and ethical obligations of clinical research, and acceptable scientific and analytic standards in the design and conduct of clinical studies. The faculty will include a diverse representation of senior FDA staff, enabling FDA to communicate directly with clinical investigators on issues of greatest importance for successful clinical research.

II. Description of the Training Course

A. Purpose

The training course is designed to provide clinical investigators with an overview of the following information:

  • The essential toxicological, pharmacological, and manufacturing data to support investigational use in humans;
  • Fundamental issues in the design and conduct of clinical trials;
  • Statistical and analytic considerations in the interpretation of trial data;
  • Appropriate safety evaluation during studies; and
  • The ethical considerations and regulatory requirements for clinical trials.

In addition, the course should do the following:

  • Foster a cadre of clinical investigators with knowledge, experience, and commitment to investigational medicine;
  • Promote communication between clinical investigators and FDA;
  • Enhance investigators' understanding of FDA's role in experimental medicine; and
  • Improve the quality of data while enhancing subject protection in the performance of clinical trials.

B. Proposed Agenda

The course will be conducted over 3 days and will comprise approximately 26 lectures, each lasting between 30 and 45 minutes. The course will be presented mainly by senior FDA staff, with guest lecturers presenting selected topics.

On November 7, 2011, the course will address the role of FDA in clinical studies, regulatory considerations for clinical trials, and review of the material generally appearing in an “investigator's brochure,” i.e., the preclinical information (toxicology, animal studies, and chemistry/manufacturing information) that supports initial clinical trials in humans. Presentations will also discuss the role of clinical pharmacology in early clinical studies and how this information is used in the design of subsequent studies. On November 8, 2011, the course will include discussions of scientific, statistical, ethical, and regulatory aspects of clinical studies. On November 9, 2011, participants will choose among three breakout sessions that explain how to put together an application to FDA for drugs, biologics, or devices.

C. Target Audience

The course is targeted at health care professionals responsible for, or involved in, the conduct and/or design of clinical trials.

Start Signature

Dated: July 25, 2011.

David Dorsey,

Acting Deputy Commissioner for Policy, Planning and Budget.

End Signature End Supplemental Information

[FR Doc. 2011-19149 Filed 7-28-11; 8:45 am]